GlassScriptPhysician profile
Joshua D Maier
NPI 1952512394
$1,386.61
in general payments reported to CMS, 2019-2025
17 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.01 · 2023: $702 · 2024: $480 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $252.02 | 2023-2025 | Prolia, Evenity, Repatha |
| Medtronic, INC. | $158.45 | 2023-2024 | Minimed 780g |
| Novo Nordisk INC | $156.66 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $118.91 | 2023-2025 | Mounjaro, Zepbound, Humulin |
| Corcept Therapeutics | $101.56 | 2023-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $100.00 | 2023-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.17 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $81.22 | 2023-2024 | |
| Dexcom, INC. | $77.34 | 2023-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $61.06 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $50.68 | 2021-2023 | Freestyle Libre 3 |
| Insulet Corporation | $47.05 | 2023-2024 | Omnipod |
| Abbvie INC. | $24.56 | 2024 | |
| Beta Bionics, INC. | $21.03 | 2024 | Ilet Bionic Pancreas |
| Horizon Therapeutics Plc | $17.84 | 2023 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $15.38 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $14.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Maier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.